Description of the medicine: Clofibratum (Clofibratum)
KLOFIBRAT (Clofibratum) *.
Ethyl a - (para-chlorophenoxy) -isobutyrate.
Synonyms: Atromidine, Clofibrate, Lipomid, Miskleron, Acolestol, Amadol, Amotril, Antilipid, Arterioflexin, Atemarol, Ateriosan, Aterosol, Athebrate, Atheromide, Atosterine, Clinofen, Clinofen, Clinofenin, Atromidin Clinofen , Fibramid, Geromid, Hypocerol, Klofibrat, Lipavil, Lipavlon, Lipomid, Liponorm, Lisisterol, Miscleron, Neo-Atromid, Nibratol, Normolipol, Regelan, Sterochol, etc.
Light yellow liquid with a faint aromatic odor. Insoluble in water, soluble in alcohol, ether and other organic solvents.
Clofibrate was the first drug from the group of derivatives of fibroic acid (fibrates), which were used as lipid-lowering agents. Currently, a number of derivatives of fibroic acid are used (see Bezafibrate, Fenofibrate, etc.).
The drugs of this group cause a decrease in the content of cholesterol and triglycerides in blood plasma, triglycerides in VLDL and cholesterol in LDL. However, they increase cholesterol in HDL (anti-atherogenic).
The decrease in cholesterol is associated with the ability of fibrates to block reductase of hydroxymethylglutaric coenzyme A (HMG CoA), which is involved in cholesterol biosynthesis, and increase cholesterol breakdown.
Fibrates also reduce platelet aggregation and blood viscosity. Reduce the level of uric acid in blood plasma. For prophylaxis, these drugs are used for familial hypercholesterolemia, hyperlipidemia and hypertriglyceridemia, idiopathic lowering of LDL.
As therapeutic agents, they are used in complex therapy for sclerosis of coronary and peripheral vessels, cerebral vessels, diabetic angiopathy and retinopathy, various diseases accompanied by hyperlipidemia, including hyperlipidemia in combination with an increase in uric acid level in blood plasma.
The drugs of the fibrate group vary in effectiveness and tolerability. For example, clofibrate is slightly less effective than new drugs (bezafibrate, fenofibrate) in this group, and more often causes side effects.
Clofibrate is prescribed orally in capsules containing 0.25 g. Take 0.5 - 0.75 g (2 - 3 capsules) 3 times a day (after meals). Treatment is usually carried out in courses of 20 to 30 days with the same intervals (4 to 6 courses).
When using fibrates, gastrointestinal disorders (nausea, vomiting), skin itching, urticaria, muscle pain (such as myositis), muscle weakness (more often in the legs) are possible; weight gain due to water retention in the body. After discontinuation of drugs, these phenomena usually disappear.
With prolonged use of clofibrate and other fibrates, intrahepatic cholestasis may develop, gallstone disease may worsen. When using clofibrate, stone formation in the gallbladder and bile ducts was observed (in connection with which this drug was no longer used in some countries).
Fibrates enhance the effect of coumarin anticoagulants, butadione, salicylates, oral antidiabetic drugs. It is necessary to use them in patients with diabetes mellitus with caution in order to avoid hypoglycemia.